Validity of targeted next-generation sequencing in routine care for identifying clinically relevant molecular profiles in non –small-cell lung cancer: results of a 2-year experience on 1,343 samples

Theranostic assays are based on single gene testing but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single gene assays. Although NGS was evaluated to screen for theranostic mutations, its usefulness in clinical practice on large series of samples remains to be demonstrated. NGS performance was assessed following guidelines. TaqMan probes and NGS were compared for their ability to detect EGFR and KRAS mutations and NGS mutation profiles were analyzed on a large series of NSCLC (n=1,343).

Source: Journal of Molecular Diagnostics - May 19, 2018 Category: Pathology Authors: Antoine Legras, Marc Barritault, Anne Tallet, Elizabeth Fabre, Alice Guyard, Bastien Rance, William Digan, Nicolas Pecuchet, Etienne Giroux-Leprieur, Catherine Julie, St éphane Jouveshomme, Véronique Duchatelle, Véronique Giraudet, Laure Gibault, Alain Tags: Regular Article Source Type: research